#USA #Los Angeles #Nordic Pharma #LACRIFILL #dry eye therapy

Nordic Pharma Presents LACRIFILL® Canalicular Gel Findings at ASCRS 2025

Nordic Pharma, a subsidiary of Nordic Group B.V., will unveil new patient data and a patient experience study regarding its innovative LACRIFILL® Canalicular Gel at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. Scheduled from April 25-28 in Los Angeles, CA, this presentation aims to demonstrate the gel's efficacy in treating dry eye symptoms.

Key Findings and Implications

Among the highlights is a recent case study published in the April issue of "Cataract & Refractive Surgery Today" (CRST), which discusses how using LACRIFILL® for lacrimal occlusion can lead to significant improvements in visual acuity and optical quality in patients experiencing fluctuating vision post-cataract surgery. The study was conducted by notable ophthalmologists Dr. Neel Desai and Dr. Subhashini Chandrasekaran.

The forthcoming May issue of CRST will elaborate on a Patient Experience survey conducted among first-time and repeat users. Impressively, 98.11% of participants confirmed they would choose another dose of LACRIFILL® Canalicular Gel in the future. This data underlines the therapy's effectiveness and its acceptance by patients and practitioners alike.

Voice of Experience

Dr. Jai Parekh, Chief Commercial Officer of Eye Care U.S., expressed excitement about sharing these promising results with attendees at ASCRS. He stated, “One year after our launch, we have substantial data from MDs and ODs showing how LACRIFILL® is transforming both practice and patient care. We are eager to present our findings at this year’s conference, which is renowned for its innovative focus.”

Dr. Priya Mathews from Center for Sight will also share her firsthand experiences with the gel, highlighting its benefits and the advantages of adopting it in practice.

Engagement with the Community

Nordic Pharma's commitment to community support will also be evident at ASCRS. The company invites attendees to visit booth #717, where they can partake in initiatives recognizing the bravery of firefighters involved in tackling recent California wildfires. Using a QR code available at the booth, visitors can contribute to the Los Angeles Fire Department Foundation. Nordic Pharma has pledged to match donations to enhance the impact of this initiative.

Further details about LACRIFILL® Canalicular Gel and ordering information can be found at lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is a privately-run, mid-sized international pharmaceutical firm specializing in developing and marketing specialty products. The company aims for portfolio expansion through targeted developments and strategic acquisitions, establishing a robust foundation in Eye Care, Rheumatology, and Women's Health. Having deep roots across Europe, Nordic Group continues to broaden its global presence through international acquisitions.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. specializes in collaborating with leading biopharmaceutical entities. It leverages its prowess in biotechnological medicine, sterile manufacturing, and advanced technologies to deliver innovative solutions to the market.

Forward-Looking Statements

This article contains forward-looking statements concerning Nordic Group and Nordic Pharma’s strategic initiatives and future developments. Actual results may differ due to various factors including market conditions and regulatory trends. Nordic Group does not commit to updating any forward-looking statements unless required by law.

For more information, please contact:
Kate Popova, Project Contracts Manager, Nordic Pharma
Phone: 610-285-1699
Email: [email protected]

Gail Feerrar, Director of Sales and Marketing, Nordic Pharma
Phone: 610-285-7152
Email: [email protected]